Megestrolacetate

Drug Overview

Megestrolacetate is a synthetic progestin hormone widely used in oncology and for treating severe weight loss. It is a cornerstone therapy for palliative care in certain cancers and for managing cancer-related cachexia and AIDS-related cachexia.

Generic Name: Megestrol Acetate
US Brand Names: Megace, Megace ES
Drug Class: Progestin (Progestational Hormone), Antineoplastic Agent, Appetite Enhancer
Route of Administration: Oral (Tablet, Oral Suspension, Concentrated Oral Suspension)
FDA Approval Status: Approved for oncological (palliative) and non-oncological (cachexia in AIDS patients) indications.

What Is It and How Does It Work? (Mechanism of Action)

Megestrol Acetate is an acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone. Its therapeutic effects are multifaceted, primarily involving two distinct mechanisms:

Antineoplastic and Antiestrogenic Activity:
- Molecular Target: Megestrol Acetate binds to and activates nuclear progesterone receptors (PRs) in the reproductive system and pituitary gland.
- Cellular Impact: The resulting ligand-receptor complex translocates to the nucleus, promoting the expression of target genes that modulate cell growth in reproductive tissues.
- Result: By mimicking progesterone’s negative feedback, it blocks the release of Luteinizing Hormone (LH) from the pituitary, which in turn inhibits estrogen release from the ovaries, impeding the growth of estrogen-sensitive tumor cells in advanced breast or endometrial cancer.
Appetite Stimulation and Anti-Cachexia Activity:
- Molecular Target: Its mechanism in cachexia is independent of the progesterone receptor and is believed to involve the Glucocorticoid Receptor (GR), especially at higher doses. Megestrol Acetate has been shown to act as a GR agonist, stimulating adipose-derived stem cells (ASCs) via GR phosphorylation.
- Cellular Impact: It also acts by downregulating pro-inflammatory cytokines (such as TNF-α, IL-1, and IL-6) that contribute to the pathogenesis of cancer-related cachexia.
- Result: This leads to increased appetite and subsequent weight gain, primarily of adipose (fat) tissue.

FDA Approved Clinical Indications

Oncological Uses:
- Palliative treatment of advanced, inoperable, recurrent, or metastatic breast cancer.
- Palliative treatment of advanced endometrial carcinoma.
Non-oncological Uses:
- Treatment of anorexia, cachexia, or unexplained significant weight loss in adult patients with a diagnosis of Acquired Immunodeficiency Syndrome (AIDS).
Common Off-Label Use:
- It is widely used as an appetite stimulant for cancer-related anorexia/cachexia in patients without AIDS, a use supported by guidelines from groups like the American Society of Clinical Oncology (ASCO).

Dosage and Administration Protocols

Megestrol Acetate dosage varies significantly based on the indication and the formulation used (tablet, standard oral suspension, or concentrated oral suspension/Megace ES).

Indication	Dosage Form/Strength	Standard Dose	Frequency and Administration	Notes on Renal/Hepatic Adjustment
Advanced Breast Cancer	Tablet (20 mg, 40 mg)	160 mg total	40 mg orally four times a day (q6hr).	Renal Impairment: Use with caution. 57–78% is excreted in the urine. Specific guidelines are not available, but caution is warranted.
Advanced Endometrial Cancer	Tablet or Suspension	40 mg to 320 mg per day	Taken orally in divided doses per day.	Hepatic Impairment: Specific guidelines for dosage adjustments are not available, but plasma concentrations can be affected. Use with caution.
Anorexia/ Cachexia (AIDS- Related)	Concentrated Oral Suspension (e.g., Megace ES 125 mg/mL)	625 mg total	Once daily by mouth.	Note: The 125 mg/mL concentrated suspension is not substitutable with other strengths due to different dosage amounts for this indication.
Anorexia/ Cachexia (AIDS- Related)	Standard Oral Suspension (40 mg/mL)	800 mg total	Once daily by mouth.	Administration: Oral suspension should be shaken well before measuring each dose.

Clinical Efficacy and Research Results

Megestrol Acetate is recognized for its palliative effects and significant impact on nutritional status.

Appetite and Weight Gain: In the setting of cancer-related cachexia (an off-label use), patients receiving the drug were 2.57 times more likely to experience appetite improvement and 1.55 times more likely to gain weight compared to those on placebo. The weight gain, while beneficial for quality of life, is noted to be primarily adipose tissue rather than skeletal muscle.
Oncological Efficacy (Advanced Cancer): For the palliative treatment of advanced breast or endometrial cancer, at least two months of therapy are typically required to determine antineoplastic effectiveness. In trials involving advanced hepatocellular carcinoma (HCC), megestrol acetate demonstrated a progressive and statistically significant suppression of tumor growth from week 6 of treatment, although one study noted no significant survival advantage in the treatment group.
Current Research (2020-2025): Recent clinical trials are investigating the use of Megestrol Acetate in combination with other agents to prevent cancer progression and manage treatment side effects:
- A Phase II trial (NCT04576104) is studying Megestrol Acetate alone or combined with metformin to prevent the progression of uterine pre-cancer (endometrial intraepithelial neoplasia) to endometrial cancer.
- A current trial (NCT06998758) is evaluating the effects of Megestrol Acetate in improving neoadjuvant chemotherapy-related weight loss, anorexia, and nutritional deterioration in patients with locally advanced colorectal cancer.

Safety Profile and Side Effects

SERIOUS ADVERSE EVENTS (Key Safety Warnings)

The most serious risks associated with Megestrol Acetate primarily stem from its hormonal and prothrombotic effects, requiring careful monitoring.

Thromboembolic Phenomena: The risk of blood clots (thrombosis, including thrombophlebitis, Deep Vein Thrombosis (DVT), and Pulmonary Embolism) is significantly increased (1.84 times the rate of placebo) and can be life-threatening.
Adrenocortical Suppression and Insufficiency: Megestrol Acetate may suppress the hypothalamic-pituitary-adrenal (HPA) axis, potentially leading to adrenal insufficiency, especially after stopping the drug or during times of stress (e.g., surgery, fever, trauma).
Hyperglycemia and Diabetes: The drug may increase or worsen blood sugar levels, increasing the risk of diabetes mellitus or making pre-existing diabetes worse.
Increased Mortality: Studies have documented a potential increased mortality risk, with a relative risk of 1.42 compared to placebo, particularly in patients with cancer cachexia.

Common Side Effects (>10%)

The following side effects are commonly reported:

Weight gain (expected for cachexia treatment)
Diarrhea/loose bowel movements
Flatulence/excess gas
Nausea
Insomnia/Trouble sleeping
Impotence (erectile dysfunction) and decreased sexual desire in men

Management Strategies for Side Effects

Diarrhea/Gas: Manage with low-fiber, high-protein/calorie foods; avoid gas-producing foods (e.g., cauliflower, cabbage); and use anti-diarrheal medicine as prescribed.
Swelling (Edema): Keep feet elevated and follow a low-salt diet.
Hyperglycemia: Patients with diabetes must maintain strict control of blood sugar levels. Immediate contact with a healthcare provider is necessary if symptoms of high blood sugar occur (e.g., increased thirst, frequent urination, fruity breath odor).
Adrenal Insufficiency: Report symptoms like extreme weakness, persistent nausea/vomiting, or fainting immediately. Supplemental corticosteroids may be required.

Connection to Stem Cell and Regenerative Medicine (If Applicable)

Research suggests Megestrol Acetate has activity relevant to regenerative medicine, independent of its established anti-cancer and anti-cachexia uses. Megestrol Acetate has been shown in vitro to increase the proliferation, migration, and differentiation of Adipose-Derived Stem Cells (ASCs). This effect is mediated by the drug’s agonist activity on the Glucocorticoid Receptor (GR), which is highly expressed in ASCs. This knowledge is being explored for potential applications in increasing the production yield and regenerative potential of ASCs for therapeutic use.

Patient Management and Practical Recommendations

Pre-Treatment Tests

Laboratory Parameters: Baseline blood glucose/A1c (especially in diabetic patients), complete blood count, and standard chemistries to assess kidney and liver function (creatinine, AST/ALT).
Pregnancy Status: Women of child-bearing potential must undergo a pregnancy test before starting treatment.

Precautions During Treatment

Contraception: Megestrol Acetate may harm an unborn baby. Women who can get pregnant must use effective contraception during therapy and for a period afterward (discuss duration with a physician).
Coagulation Risk: Patients with a history of blood clots or other risk factors for thromboembolic events must be closely monitored.
Geriatric Use: Older adults may be at greater risk for side effects, requiring caution and potential dose adjustments due to age-related decline in liver, kidney, or heart function.

Do’s and Don’ts

Do’s	Don’ts
DO: Take the medicine exactly as prescribed and at the same time(s) every day.	DON’T: Stop taking Megestrol Acetate abruptly without consulting your doctor, as this can trigger adrenal insufficiency.
DO: Shake the oral suspension well before measuring each dose.	DON’T: Assume you cannot become pregnant if you are a premenopausal woman; use reliable birth control.
DO: Tell your healthcare provider immediately if you experience symptoms of a blood clot (e.g., sudden trouble breathing, chest pain, or painful swelling/redness in a leg).	DON’T: Breastfeed while taking this medication, as it passes into breast milk and may harm the infant.
DO: Monitor blood sugar closely, especially if you have diabetes.	DON’T: Substitute different strengths of the oral suspension (e.g., 40 mg/mL vs. 125 mg/mL) for AIDS-related cachexia, as dosages differ.

Legal Disclaimer

This guide is for informational purposes only and is intended for international patients and healthcare professionals. It does not replace professional medical advice, diagnosis, or treatment. Dosing and protocols may vary by patient status and local regulatory guidelines. Always consult with a qualified oncologist or healthcare provider regarding specific medical conditions.